TATsukasa Aihara

Tsukasa Aihara

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tsukasa Aihara has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Outcomes of Combined Hepatectomy and Intraoperative Ablation for Multiple Colorectal Liver Metastases: A Single-Center Retrospective Study

    by Tsukasa Aihara, Shinichi Ikuta, Takayoshi Nakajima, Shinta Nagano, Toshimitsu Iwasaki, Hidenori Yanagi, Naoki Yamanaka

    Introduction: Radical hepatectomy is the standard curative treatment for colorectal liver metastases (CRLMs). However, extensive resection may be contraindicated in patients with insufficient liver reserve or anatomically complex disease. Although ablation therapy is generally not recommended as a primary curative modality in current guidelines, intraoperative ablation may facilitate parenchymal-sparing, curative-intent treatment in selected high-risk patients. Methods: This retrospective cohort study included 118 patients who underwent curative-intent hepatectomy for multiple CRLM. Patients were categorized into hepatectomy-only (Hx) and hepatectomy plus intraoperative ablation (Hx + Abl) groups, and propensity score matching (PSM) generated 29 balanced pairs. Overall survival (OS) and hepatic progression-free survival (HPFS) were compared using a log-rank test. Cox regression identified predictors of OS, and receiver operating characteristic (ROC) analysis evaluated tumor size associated with local recurrence after ablation. Results: Before PSM, the HX + Abl group showed higher tumor burden and Beppu scores, and demonstrated inferior OS and HPFS. After PSM, oncological outcomes were comparable. Perioperative outcomes, including major complications and post-hepatectomy liver failure (PHLF), were similar. Preoperative chemotherapy was an independent predictor of OS. Among 99 ablated tumors, local recurrence occurred in 12 lesions, and ROC analysis identified tumor size ≤ 15mm as the optimal cutoff predicting local recurrence. Conclusions: In selected high-risk CRLM patients, hepatectomy with intraoperative ablation had no statistically significant difference in OS and HPFS compared with hepatectomy alone without increasing major complications or PHLF.

  • Open Access

    Construction and validation of a preoperative prognostic model integrating the novel aspartate aminotransferase-albumin score for hepatocellular carcinoma patients undergoing liver resection

    by Shinichi Ikuta, Tsukasa Aihara, Meidai Kasai, Takayoshi Nakajima, Naoki Yamanaka

    Shinichi Ikuta, Tsukasa Aihara, Meidai Kasai, Takayoshi Nakajima, Naoki Yamanaka. Ann Hepatobiliary Pancreat Surg -0001;0:. https://doi.org/10.14701/ahbps.24-110

  • Open Access

    Clinical Features of Resected Pancreatic Cancer Diagnosed during Follow-Up of Chronic Liver Disease

    by Takayoshi Nakajima, Shinichi Ikuta, Tsukasa Aihara, Masataka Fujikawa, Noriko Ichise, Meidai Kasai, Ryo Okamoto, Yoshihiko Nakamoto, Hidenori Yanagi, Naoki Yamanaka

    目的:膵癌の予後向上には早期診断が重要だがそのアルゴリズムは確立されていない.本研究では慢性肝疾患(chronic liver disease;以下,CLDと略記)に対する肝細胞癌(hepatocellular carcinoma;以下,HCCと略記)のサーベイランス中に診断され,切除に至った膵癌の特徴について検討した.方法:2011~2019年に当科で切除を行った膵癌110例を,CLDのフォロー中に診断された16例(HCC surveillance群;以下,HS群と略記)とその他94例(non-surveillance群;以下,NS群と略記)に大別し,臨床病理学的特徴を後方視的に比較検討した.結果:HS群の内3例はHCCの治療歴を有していた.HS群はNS群より診断時の有症状率が低くresectable膵癌の割合が高率であった.また,主要脈管合併切除の併施率が低く,R0切除率が高く,早期ステージ(0~IIA)の占める割合が有意に高かった.HS群では13例(81.3%)がHCCサーベイランス目的の画像検査を契機に膵癌が発見されていたが,NS群で画像診断を契機としたものは5例(5.3%)に止まった.結語:CLDにおけるHCCサーベイランスは無症候かつ比較的早期の膵癌および切除可能膵癌の発見に寄与する可能性がある.肝疾患フォロー中の画像診断では肝臓だけでなく膵臓にも目を配る姿勢が肝要である.

  • Open Access

    A Case of Intrahepatic Cholangiocarcinoma with Recurrence-Free Survival for Twelve Years after Five Resections for Intrahepatic Recurrence after Initial Hepatectomy

    by Takayoshi Nakajima, Shinichi Ikuta, Noriko Ichise, Meidai Kasai, Ikumi Hamano, Ryo Okamoto, Yoshihiko Nakamoto, Tsukasa Aihara, Hidenori Yanagi, Ayako Kakuno, et al.

    症例は73歳の女性で,上腹部痛を契機に認められた4.5 cm大の肝内胆管癌(intrahepatic cholangiocarcinoma;以下,ICCと略記)を疑って肝右3区域切除術を施行,中分化型の腫瘤形成型ICCと診断された.再肝部分切除術は,①初回術後2年1か月,肝S1の2 cm大の単発再発,②初回術後2年9か月,肝S1の3 cm大の単発再発,③初回術後3年8か月,肝S2の1.5 cm大の単発再発,④初回術後5年9か月,肝S3の2 cm大の単発再発,⑤初回術後6年11か月,肝S2に3 cm大の単発再発,に対して行った.再切除した腫瘍はいずれも中分化型の腫瘤形成型ICCの所見で被膜浸潤および脈管侵襲を認めなかった.現在,初回手術後12年以上経過したが無再発生存中である.ICC切除例として希少な症例と考えられ報告する.


  • Comparative study of percutaneous radiofrequency ablation and hepatic resection for small, poorly differentiated hepatocellular carcinomas

    by Hiroya Iida, Tsukasa Aihara, Shinichi Ikuta, Naoki Yamanaka

    Histologically, poorly differentiated hepatocellular carcinomas (HCC) are considered highly malignant. Here, we aimed to evaluate the relative efficacy and safety of hepatic resection or radiofrequency ablation (RFA) for treating this malignancy. Between April 2004 and May 2011, we enrolled 48 patients who had poorly differentiated HCC that had been diagnosed postoperatively by pathological assessment. All the tumors had a maximum diameter of 3 cm and all patients had three or less tumors. Fifteen of these patients underwent hepatic resection (HR group) and 33 patients underwent RFA (RF group). The patient background, tumor characteristics, overall survival rate and recurrence-free survival rate were assessed in both groups. The mean maximum tumor diameter was 2.5 and 2.0 cm in the HR and RF groups, respectively. The prothrombin activity level was 94% and 86% in the HR and RF groups, respectively. The 1-, 3- and 5-year cumulative survival rates were 89.1%, 68.7% and 68.7%, respectively, in the HR group, and 59.2%, 40.9% and 32.7%, respectively, in the RF group. The 1-, 3- and 5-year recurrence-free survival rates were 85.1%, 64.8% and 48.6%, respectively, in the HR group, and 29.0%, 7.2% and 7.2%, respectively, in the RF group. There was a significant difference between these groups (P < 0.05). As hepatic resection has greater efficacy than RFA in the treatment of poorly differentiated HCC, even in cases with a small tumor size, we recommend its use for this malignancy.